Two more biopharma firms priced initial public offerings (IPOs), though Adamas Pharmaceuticals Inc. and Cerulean Pharmaceuticals Inc. received lukewarm welcomes on Nasdaq Thursday, as the Nasdaq Biotechnology Index – after a short-lived rally the day before – took another slide.